We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.
For more information visit our privacy policy.TRANSACTION AGREEMENTTransaction Agreement • August 4th, 2024 • Delaware
Contract Type FiledAugust 4th, 2024 JurisdictionTHIS TRANSACTION AGREEMENT (this “Agreement”), dated August 27, 2018, is entered into by and among CytoDyn Inc., a Delaware corporation (the “Company”), Point NewCo Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“NewCo”), Point Merger Corp., a Delaware corporation and wholly-owned subsidiary of NewCo (“Merger Sub”), ProstaGene, LLC, a Delaware limited liability company (“Seller”), and (solely with respect to the representations, warranties and obligations set forth in Sections 5.9(b), 7.8, 14.1(c) and 14.4(f)) Dr. Richard G. Pestell (“Dr. Pestell”). Capitalized terms used herein shall have the meaning assigned to them in Appendix A.